Consequences of p16 tumor suppressor gene inactivation in mycosis fungoides and Sézary syndrome and role of the bmi-1 and ras oncogenes in disease progression

Human Pathology

Volumn 38, Issue 7, 2007, Pages 995-1002

  Zhang, Chunlei ^a   Toulev, Albena ^a   Kamarashev, Jivko ^a   Qin, Jian Zhong ^a   Dummer, Reinhard ^a   Döbbeling, Udo ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Cell cycle regulators; Cutaneous T cell lymphoma; Oncogenes

Indexed keywords

CYCLIN D; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; RETINOBLASTOMA PROTEIN;

ANTIBODY SPECIFICITY; ARTICLE; CELL CYCLE; CELL LINE; DISEASE COURSE; GENE ACTIVATION; GENE DELETION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE PROLIFERATION; METHYLATION; MYCOSIS FUNGOIDES; ONCOGENE RAS; SEZARY SYNDROME; SKIN DEFECT; STAINING; T LYMPHOCYTE; TUMOR SUPPRESSOR GENE;

CELL PROLIFERATION; DISEASE PROGRESSION; GENES, P16; GENES, RAS; HUMANS; MYCOSIS FUNGOIDES; NUCLEAR PROTEINS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS; RETINOBLASTOMA PROTEIN; SEZARY SYNDROME; SKIN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 34250174795     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2006.10.021     Document Type: Article

References (36)

1. Burg G., Kempf W., Häffner A.C., et al. Cutaneous lymphomas. Curr Probl Dermatol 9 (1997) 139-204
2. Girardi M., and Edelson R.L. Cutaneous T-cell lymphoma: pathogenesis and treatment. Oncology 14 (2000) 1061-1070
3. Zhang C., Kamarashev J., Qin J.Z., Burg G., Dummer R., and Döbbeling U. Expression of apoptosis regulators in cutaneous T cell lymphoma. J Path 200 (2003) 249-254
4. Lauritzen A.F., Vejlsgaard G.L., Hou-Jensen K., and Ralfkiaer E. p53 protein expression in cutaneous T-cell lymphoma. Br J Dermatol 133 (1995) 32-36
5. de Misa R.F., Azana J.M., Harto A., Bellas C., and Ledo A. Infrequent expression of protein p53 in epidermotropic variants of cutaneous T-cell lymphoma. J Dermatol 22 (1995) 524-528
6. Li G., Chooback L., Rook A.H., Felix C.A., Lessin S.R., and Salhany K.E. Overexpression of p53 in cutaneous T cell lymphoma: relationship to large cell transformation and disease progression. J Invest Dermatol 110 (1998) 767-770
7. Marrogi A.J., Khan M.A., Vonderheid E.C., Wood G.S., and McBurney E. p53 tumor suppressor gene mutations in transformed cutaneous T-cell lymphoma: a study of 12 cases. J Cutan Pathol 26 (1999) 369-378
8. van Haselen C.W., Vermeer M.H., Toonstra J., et al. p53 and bcl-2 expression do not correlate with prognosis in primary cutaneous large T-cell lymphomas. J Cutan Pathol 24 (1997) 462-467
9. Serrano M., Hannon G.J., and Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclinD/CDK4. Nature 366 (1993) 704-707
10. Hannon G.J., and Beach D. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 371 (1994) 257-261
11. INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes & Dev 8 (1994) 2939-2952
12. Chan F.K.M., Zhang J., Cheng L., Shapiro D.N., and Winoto A. Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16 INK. Mol Cell Biol 15 (1995) 2682-2688
13. Zhang H.S., Postigo A.A., and Dean D.C. Active transcriptional repression by the Rb-E2F complex mediates G1 arrest triggered by p16INK4A, TGF-beta and contact inhibition. Cell 97 (1999) 53-61
14. Kamb A., Gruis N.A., Weaver-Feldhaus J., et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 264 (1994) 436-440
15. Nobori T., Miura K., Wu D.J., Lois A., Takabayashi K., and Carson D.A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368 (1994) 753-756
16. Okamoto A., Demetrick D.J., Spillare E.A., et al. Mutations and altered expression of p16INK in human cancer. Proc Natl Acad Sci U S A 91 (1995) 11045-11049
17. Navas I.C., Ortiz-Romero P.L., Villuendas R., et al. p16(INK4a) gene alterations are frequent in lesions of mycosis fungoides. Am J Pathol 156 (2000) 1565-1572
18. Scarisbrick J.J., Woolford A.J., Calonje E., et al. Frequent abnormalities of the p15 and p16 genes in mycosis fungoides and Sézary syndrome. J Invest Dermatol 118 (2002) 493-499
19. Nagasawa Z.Q., Raghunath P.N., Wong H.Y., et al. Multi-gene epigenetic silencing of tumor suppressor genes in T-cell lymphoma cells; delayed expression of the p16 protein upon reversal of the silencing. Leuk Res 30 (2006) 303-312
20. Jacobs J.J., Kieboom K., Marino S., DePinho R.A., and van Lohuizen M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 397 (1999) 164-168
21. van Kemenade F.J., Raaphorst F.M., Blokzijl T., et al. Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood 97 (2001) 3896-3901
22. Raaphorst F.M., van Kemenade F.J., Blokzijl T., et al. Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin's disease. Am J Pathol 15 (2000) 709-715
23. Bea S., Tort F., Pinyol M., et al. BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res 61 (2001) 2409-2412
24. Vonlanthen S., Heighway J., Altermatt H.J., et al. The bmi-1 oncoprotein is differently expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br J Cancer 84 (2001) 1372-1376
25. Jacobs J.J., Scheijen B., Voncken J.W., Kieboom K., Berns A., and van Lohuizen M. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes & Dev 13 (1999) 2678-2690
26. Kanavaros P., Ioannidou D., Tzardi M., et al. Mycosis fungoides: expression of c-myc p62 p53, bcl-2 and PCNA proteins and absence of association with Epstein-Barr virus. Pathol Res Pract 190 (1994) 767-774
27. Qin J.-Z., Dummer R., Burg G., and Döbbeling U. Constitutive and IL-7/ IL-15 stimulated DNA-binding of Myc, Jun, and novel Myc-like proteins in cutaneous T cell lymphoma (CTCL) cells. Blood 93 (1999) 260-267
28. Raaphorst F.M., Otte A.P., van Kemenade F.J., et al. Distinct BMI-1 and EZH2 expression patterns in thymocytes and mature T cells suggest a role for Polycomb genes in human T cell differentiation. J Immunol 166 (2001) 5925-5934
29. Lazarov M., Kubo Y., Cai T., et al. CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis. Nat Med 8 (2002) 1105-1114
30. Chin L., Tam A., Pomerantz J., et al. Essential role for oncogenic ras in tumour maintenance. Nature 400 (1999) 468-472
31. Döbbeling U., Boni R., Häffner A., Dummer R., and Burg G. Method for simultaneous RNA and DNA isolation from biopsy material, culture cells, plants and bacteria. BioTechniques 22 (1997) 88-90
32. Döbbeling U., Dummer R., Hess Schmid M., and Burg G. Lack of expression of the recombination activating genes RAG-1 and RAG-2 in cutaneous T cell lymphoma (CTCL): pathogenetic implications. Clin Exp Dermatol 22 (1997) 230-233
33. Peris K., Stanta G., Fargnoli M.C., et al. Reduced expression of CDKN2a/P16INK4a in mycosis fungoides. Arch Dermatol Res 291 (1999) 207-211
34. Bunn P.A., Edelson R., Ford S.S., and Shackney S.E. Patterns of cell proliferation and cell migration in the Sézary syndrome. Blood 57 (1981) 452-463
35. Ferreux E., Lont A.P., Horenblas S., et al. Evidence for at least three alternative mechanisms targeting the p16 INK4A/cyclin D/Rb pathway in penile carcinoma, one of which is mediated by high-risk human papillomavirus. J Path 201 (2003) 109-118
36. Cahill M.A., Janknecht R., and Nordheim A. Signalling pathways: jack of all cascades. Curr Biol 6 (1996) 16-19